Fibromyalgia

Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress

Retrieved on: 
Monday, October 30, 2023

CHATHAM, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced data from two oral presentations which were delivered recently at the American College of Surgeons (ACS) Clinical Congress 2023, and The International Pancreas and Islet Transplant Association (IPITA), the International Xenotransplantation Association (IXA), and the Cell Transplant and Regenerative Medicine Society (CTRMS) Joint Congress by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in October 2023. The data involve Tonix’s TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) which is currently in Phase 1 development for the prevention of organ transplant rejection. Copies of the presentations are available under the Scientific Presentations tab of the Tonix Pharmaceuticals website at www.tonixpharma.com.

Key Points: 
  • The data involve Tonix’s TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) which is currently in Phase 1 development for the prevention of organ transplant rejection.
  • Copies of the presentations are available under the Scientific Presentations tab of the Tonix Pharmaceuticals website at www.tonixpharma.com .
  • include data demonstrating the use of TNX-1500 as maintenance therapy after xeno heart transplant in non-human primates.
  • In both studies, genetically engineered (GE) pigs in baboon transplants were treated with cold-perfused ischemia minimization and a novel costimulation-based immunosuppressive regimen including TNX-1500.

Key Drivers of Growth in Orthopedic Regenerative Surgical Products Market: Aging Population and Technological Innovations - ResearchAndMarkets.com

Retrieved on: 
Monday, October 30, 2023

The global orthopedic regenerative surgical products market size is anticipated to reach USD 5.63 billion by 2030.

Key Points: 
  • The global orthopedic regenerative surgical products market size is anticipated to reach USD 5.63 billion by 2030.
  • The primary factors boosting the market growth include the growing older population, easy availability of orthopedic treatments & procedures, and technological advancements.
  • For instance, osteoarthritis, an orthopedic ailment, has been considered the major factor of chronic disability in the geriatric population (aged above 70 years).
  • Thus, the growing prevalence of orthopedic ailments and the rising aging population & obesity cases are expected to drive market growth.

NeuroMetrix Reports Q3 2023 Business Highlights

Retrieved on: 
Thursday, October 26, 2023

WOBURN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023.

Key Points: 
  • WOBURN, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported business and financial highlights for the quarter and nine month period ended September 30, 2023.
  • Financial results in Q3 2023 were consistent with Company expectations and reflect the substantial changes to Medicare Advantage risk-adjustment reimbursement implemented by CMS in Q1 2023.
  • Revenue in Q3 2023 of $1.2 million was lower by $0.8 million or 39% from Q3 2022 primarily due to reduced sales volume for DPNCheck.
  • The Q3 2023 net loss was $1.8 million ($0.21 per share) versus a net loss of $1.6 million ($0.23 per share) in Q3 2022.

Neuragenex Brings Innovative Fibromyalgia Treatment to Patients Across the US

Retrieved on: 
Wednesday, October 25, 2023

GULBERT, Ariz., Oct. 25, 2023 /PRNewswire/ -- Neuragenex, the national healthcare provider focused on non-pharmaceutical pain treatment, announced its continued expansion to bring relief to fibromyalgia patients across the country.

Key Points: 
  • GULBERT, Ariz., Oct. 25, 2023 /PRNewswire/ -- Neuragenex, the national healthcare provider focused on non-pharmaceutical pain treatment, announced its continued expansion to bring relief to fibromyalgia patients across the country.
  • Patients often struggle for years to get an accurate diagnosis, shuffling between doctors while their quality of life deteriorates.
  • Through their proprietary Neurofunctional Pain Management protocol, Neuragenex clinicians identify and treat the root physiological factors that contribute to fibromyalgia pain and dysfunction.
  • For more information about Fibromyalgia treatment solutions or about Neuragenex and its new clinic locations, please visit the company website at www.neuragenex.com .

National Bank donates $1.7M to Fuel Ground-breaking Health Research at the RI-MUHC

Retrieved on: 
Wednesday, October 18, 2023

These researchers are based at the RI-MUHC and other top health research institutions in Montreal.

Key Points: 
  • These researchers are based at the RI-MUHC and other top health research institutions in Montreal.
  • This generous donation demonstrates National Bank’s commitment to fostering collaboration and innovation within the medical field, and will position Quebec as a global leader in microbiome research.
  • The Bank takes great pride in supporting the exceptional endeavours underway at MI4 and at the Research Institute of the MUHC.
  • "Microbiome research has the potential to unlock a vast array of new knowledge about our health.

Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference

Retrieved on: 
Thursday, October 12, 2023

CHATHAM, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m.

Key Points: 
  • CHATHAM, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Thursday, October 19, 2023, at 8:00 a.m.
  • Investors interested in arranging a meeting with the Company’s management during the conference should contact the ThinkEquity conference coordinator.
  • A webcast of the presentation will be available under the IR Events tab of the Tonix website at www.tonixpharma.com .
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Retrieved on: 
Thursday, October 12, 2023

ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID , announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the annual ThinkEquity Conference on Thursday, October 19, 2023 at 11:00 am ET in New York, NY.

Key Points: 
  • ATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases such as fibromyalgia and Long-COVID , announced today that Greg Duncan, Chairman and Chief Executive Officer, will present at the annual ThinkEquity Conference on Thursday, October 19, 2023 at 11:00 am ET in New York, NY.
  • The live and archived webcast of the session may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations .
  • The ThinkEquity Conference will gather industry insiders, investors and leading executives for a full day of company presentations, one-on-one investor meetings, networking and more.
  • Featured sectors include AI/Big Data Technology, Biotechnology, EV/EV Infrastructure, Metals & Mining and Energy.

Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe

Retrieved on: 
Wednesday, October 11, 2023

A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.

Key Points: 
  • A copy of the Company’s presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference.
  • Additional meeting information can be found on the World Vaccine Congress website here .
  • Tonix is a biopharmaceutical company focused on commercializing, developing, discovering and licensing therapeutics to treat and prevent human disease and alleviate suffering.
  • TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases.

NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia

Retrieved on: 
Monday, October 2, 2023

WOBURN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA).

Key Points: 
  • WOBURN, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) announced that it has been selected as a Proud Sponsor of the National Fibromyalgia Association (NFA).
  • As a Proud Sponsor NeuroMetrix will support the NFA’s mission to provide education, support, and advocacy for people living with fibromyalgia and their loved ones.
  • “We are delighted to work with the National Fibromyalgia Association to further our mutual commitment to the fibromyalgia community,” said Shai N. Gozani, M.D., Ph.D., CEO of NeuroMetrix.
  • The sale, distribution, and use of Quell Fibromyalgia is restricted to prescription use in accordance with 21 CFR 801.109.

Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering

Retrieved on: 
Friday, September 29, 2023

The closing of the public offering is expected to take place on or about October 3, 2023, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The closing of the public offering is expected to take place on or about October 3, 2023, subject to the satisfaction of customary closing conditions.
  • The gross proceeds of the offering will be approximately $4.5 million before deducting placement agent fees and other estimated offering expenses payable by the Company.
  • Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as co-placement agent for the offering.
  • The offering will be made only by means of a prospectus supplement and accompanying base prospectus, as may be further supplemented by any free writing prospectus and/or pricing supplement that Tonix may file with the SEC.